Skip to main content
Erschienen in: Journal of Cardiothoracic Surgery 1/2021

Open Access 01.12.2021 | Review

The use of fibrinolytic therapy for parapneumonic effusion in pregnancy: a case report and a review

verfasst von: Awrad Nasralla, Bryce Laing, Simon R. Turner

Erschienen in: Journal of Cardiothoracic Surgery | Ausgabe 1/2021

Abstract

The use of intrapleural fibrinolytics for complicated parapneumonic effusion has been shown to be an effective and safe alternative to surgery. However, there is limited evidence about its use during pregnancy. We present a case and a review of the literature of pregnant women who had successful treatment of their complicated parapneumonic effusion with intrapleural fibrinolytics. To our knowledge this is the first review of cases of pregnant women with parapneumonic effusion managed with intrapleural fibrinolytic.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
tPA
Tissue plasminogen activator, alteplase
CT
Computed tomography
MRI
Magnetic resonance imaging
CXR
Chest X-ray
ICU
Intensive Care Unit
WBC
White blood cell count

Introduction

The incidence of pneumonia in pregnant women is similar to the general population. It is associated with serious complications such as empyema (8%), bacteremia (16%), and respiratory failure (20%). The management of complicated parapneumonic effusion consist of antibiotics, chest tube insertion, and fibrinolytics or surgery [1, 2]. The use of fibrinolytics had decreased the rate of surgical intervention for empyema from 80 to 30% [3]. However, there are no randomized controlled trials in pregnant patients to demonstrate safety of intrapleural fibrinolytics. Data from intravenous fibrinolytics for acute thrombotic events suggest that the complication rate is similar in pregnant and nonpregnant women [4]. Herein, we present a case and a literature review for cases of pregnant women with parapneumonic effusion managed with intrapleural fibrinolytic therapy.

Methods

We present a case of a 23-week pregnant patient with empyema who was managed with thoracostomy and fibrinolytic therapy. She presented while out of country with lower respiratory tract symptoms. During admission she developed septic shock and a small left pleural effusion. Initially she was treated with antibiotics and vasopressors. Once stabilized she traveled back to her home city where she was readmitted due to a progressively enlarging left pleural effusion.
A comprehensive search was performed using the Medline, Cochrane, Pubmed, and Scopus data bases. Abstracts included based on the following inclusion criteria: (1) Pregnancy, (2) Empyema or parapneumonic effusion, (3) fibrinolytic therapy. The primary outcome of interest was resolution of the effusion clinically and radiologically. Secondary outcomes included fetus condition and follow-up after delivery.

Case presentation

A 35-year-old pregnant, gestational age of 23 weeks, presented while out of country with 10 days history of dry cough, fatigue, and fever. On presentation she had left-sided pleuritic chest pain, and was found to be hypotensive (systolic blood pressure of 70), with oxygen saturation at 92% on room air, afebrile (36.80 °C), with respiratory rate of 25/min, and heart rate of 110/min. On physical examination, she was alert, and she had decreased breath sounds on the left side. She was admitted to the intensive care unit (ICU) with a diagnosis of septic shock secondary to pneumonia. Chest x-ray (CXR) and computed tomography (CT) of the chest revealed left side pneumonia. Significant laboratory finding were WBC of 25 and blood culture showing pansensitive group A streptococcus. She was given 5L of IV fluids and she was started on norepinephrine, ceftriaxone, and azithromycin. Fetal heart rate, assessed via Doppler, was within normal limits.
After several days of treatment with IV ceftriaxone the patient was discharged home, with a plan to continue IV antibiotics for 2 weeks and to follow up with her family doctor. During this follow-up clinic visit, she was afebrile (36.1 °C), her blood pressure was 107/65, heart rate of 116, oxygen saturation at 95% on room air. She had reduced breath sounds over the left side of her chest. Her WBC was 25.7. Repeated blood cultures were negative. Repeated CXR revealed a large left pleural effusion with tracheal shift to the right side (Fig. 1). An 8- French pig tail was inserted under ultrasound (US) guidance to drain the left pleural effusion. Initially 240 ml of cloudy pleural fluid was drained, and pleural fluid culture was negative in the setting of ongoing treatment with an antibiotic. CXR showed incomplete resolution of left pleural effusion (Fig. 2). A multidisciplinary discussion about the advantages and disadvantage of both surgery and intrapleural thrombolytics was had with the patient. She decided to proceed with intrapleural fibrinolytics, accepting the potential risk of bleeding and possible fetal complications. One dose of 5 mg of tissue plasminogen activator (tPA) diluted in 50 ml of normal saline was given, after which a significant drainage of the left pig tail was noticed. A Fetal ultrasound following the administration of intrapleural fibrinolytics was reassuring.
The pigtail was removed the day after, she was discharged home with IV Penicillin G for 2 weeks, then she was switched to Amoxicillin to complete a total of 4 weeks of treatment. Her WBC normalized. Her follow up CXR showed near complete resolution of the pleural effusion. However, a repeated CXR after 6 months showed complete resolution of the effusion, and minimal residual pleural thickening in the left costophrenic angle (Fig. 3). She a had a healthy term baby via vaginal delivery.

Results

There are 5 reported cases of treatment of complex pleural effusions in pregnant women using fibrinolytics in the literature. Mean age was 31.2 years, mean gestational age was 28.2 weeks. Management consisted of antibiotic, thoracostomy, and intrapleural fibrinolytics. All had resolution of the symptoms and pleural effusion with avoidance of surgery. Images utilized were CXR, CT scan, or magnetic resonance imaging (MRI). In all the cases the fetus status was assessed with sonography or continuous fetal cardiotocography. No complications in the form of bleeding or other morbidity to the pregnant woman nor her baby was reported.
The most commonly used fibrinolytics were streptokinase or alteplase, and the doses of fibrinolytic therapy used varied among the cases reported (Table 1).
Table 1
Cases of complicated parapneumonic effusion in pregnant ladies managed with intrapleural fibrinolytic therapy
Publication year
Author
Age
GA
Fibrinolytic therapy
2009
Samuel Nir [12]
24
33
Streptokinase (250,000 U/Q 8 h), total 9 doses over 72 h
2012
Hakki Ulutas [1]
22
24
Streptokinase 250,000 U/day, 2 doses
2012
Hakki Ulutas [1]
39
29
Streptokinase 250,000 U/day, 4 doses
2017
Heather Torbic [9]
35
32
2.5 mg of tPA, 1 dose
2019
Diana Amariei [8]
32
28
Two doses:2.5 mg of alteplase and 5 mg of dornase, third dose of alteplase of 5 mg
2021
Awrad Nasralla
35
23
5 mg of tPA, 1 dose

Discussion

The use of intrapleural fibrinolytic therapy for complicated parapneumonic effusion during pregnancy is based on case reports [6]. It has been documented that the use of systematic fibrinolytics for thromboembolic disease in pregnant women was not associated with significant adverse events in comparison to general population [4]. In addition, several factors make intrapleural fibrinolytics attractive for complicated parapneumonic effusion. Those include the lower dose used for intrapleural treatment, short half-life, large molecular size with low systemic absorption, and no reported teratogenic effects on humans [7, 8]. However, side effects may be encountered such fever, allergic reactions, chest pain, and increased risk of bleeding. Of those the most worrisome is the pleural bleeding although it is uncommon, and can often be detected immediately by looking at the chest tube output. The risk of bleeding is higher in patients on anticoagulation, or those with coagulopathic disorders or renal failure [3, 9, 10].
This warrants a thorough discussion with patient about the potential adverse events. A multidisciplinary approach is recommended including obstetrics, pulmonology, infectious disease and thoracic surgery teams. In terms of appropriate dose of intrapleural fibrinolytics, we think that should be individualized to each case based on the size of the effusion, and the presence of loculation. It is worth mentioning that some cases reported the use intrapleural streptokinase to treat complicated parapneumonic effusion with success without adverse events on newborn [11].

Conclusion

Management of parapneumonic effusion during pregnancy using fibrinolytic therapy is based on case reports. It seems to be a safe and effective alternative to surgery. A multidisciplinary approach is recommended, with early referral to thoracic surgery. The crucial aspect is the discussion between the patient and the medical team outlining the possible risk and benefits.

Acknowledgements

Not applicable.

Declarations

Not applicable.
Consent was obtained from the patient.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Ulutas H, Yekeler E, Ali Sak ZH, Doru I, Kuzucu A. Fibrinolytic therapy for parapneumonic empyema during pregnancy. Respir Med Case Rep. 2012;5:55–8.PubMed Ulutas H, Yekeler E, Ali Sak ZH, Doru I, Kuzucu A. Fibrinolytic therapy for parapneumonic empyema during pregnancy. Respir Med Case Rep. 2012;5:55–8.PubMed
2.
Zurück zum Zitat Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med. 2005;33(10 Suppl):S390–7.CrossRef Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med. 2005;33(10 Suppl):S390–7.CrossRef
3.
Zurück zum Zitat Charlie Strange. Management and prognosis of parapneumonic pleural effusion and empyema in adults—UpToDate. 2021 [cited 2021 Mar 15]. Charlie Strange. Management and prognosis of parapneumonic pleural effusion and empyema in adults—UpToDate. 2021 [cited 2021 Mar 15].
4.
Zurück zum Zitat Sousa Gomes M, Guimarães M, Montenegro N. Thrombolysis in pregnancy: a literature review. J Matern Fetal Neonatal Med. 2019;32(14):2418–28.CrossRef Sousa Gomes M, Guimarães M, Montenegro N. Thrombolysis in pregnancy: a literature review. J Matern Fetal Neonatal Med. 2019;32(14):2418–28.CrossRef
5.
Zurück zum Zitat Whang B. Thoracic surgery in the pregnant patient. Thorac Surg Clin. 2018;28(1):1–7.CrossRef Whang B. Thoracic surgery in the pregnant patient. Thorac Surg Clin. 2018;28(1):1–7.CrossRef
6.
Zurück zum Zitat Dikensoy E, Dikensoy Ö, Light RW. Management of parapneumonic effusion in pregnant women. Tuberk Toraks. 2018;66(1):64–7.CrossRef Dikensoy E, Dikensoy Ö, Light RW. Management of parapneumonic effusion in pregnant women. Tuberk Toraks. 2018;66(1):64–7.CrossRef
7.
Zurück zum Zitat Berglin E, Ekroth R, Teger-Nilsson AC, William-Olsson G. Intrapleural instillation of streptokinase. Effects on systemic fibrinolysis. Thorac Cardiovasc Surg. 1981;29(2):124–6.CrossRef Berglin E, Ekroth R, Teger-Nilsson AC, William-Olsson G. Intrapleural instillation of streptokinase. Effects on systemic fibrinolysis. Thorac Cardiovasc Surg. 1981;29(2):124–6.CrossRef
8.
Zurück zum Zitat Amariei DE, Tran B-C, Yao R, Britt EM, Holden VK, Sachdeva A, et al. Intrapleural alteplase and dornase in a pregnant woman with complicated parapneumonic effusion. Ann Thorac Surg. 2019;108(5):e293–4.CrossRef Amariei DE, Tran B-C, Yao R, Britt EM, Holden VK, Sachdeva A, et al. Intrapleural alteplase and dornase in a pregnant woman with complicated parapneumonic effusion. Ann Thorac Surg. 2019;108(5):e293–4.CrossRef
9.
Zurück zum Zitat Torbic H, Inaty H, Raja S, Choi H. Safe administration of intrapleural alteplase during pregnancy. J Thorac Dis. 2017;9(9):E801–4.CrossRef Torbic H, Inaty H, Raja S, Choi H. Safe administration of intrapleural alteplase during pregnancy. J Thorac Dis. 2017;9(9):E801–4.CrossRef
10.
Zurück zum Zitat Piccolo F, Pitman N, Bhatnagar R, Popowicz N, Smith NA, Brockway B, et al. Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery. Ann Am Thorac Soc. 2014;11(9):1419–25.CrossRef Piccolo F, Pitman N, Bhatnagar R, Popowicz N, Smith NA, Brockway B, et al. Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery. Ann Am Thorac Soc. 2014;11(9):1419–25.CrossRef
11.
Zurück zum Zitat Yigit AK, Yilmaz Y, Erdeve O, Gokce IK, Oguz SS, Uras N, et al. Intrapleural streptokinase for the treatment of complicated parapneumonic effusion and empyema in 2 newborns. J Pediatr Surg. 2012;47(10):e41–4.CrossRef Yigit AK, Yilmaz Y, Erdeve O, Gokce IK, Oguz SS, Uras N, et al. Intrapleural streptokinase for the treatment of complicated parapneumonic effusion and empyema in 2 newborns. J Pediatr Surg. 2012;47(10):e41–4.CrossRef
12.
Zurück zum Zitat Nir S, Gadi L, Mony S, Meir M, Jaime G, Amir E, et al. Successful use of streptokinase for the treatment of empyema thoracis during advanced pregnancy: a case report. Respir Med CME. 2009;2(1):21–4.CrossRef Nir S, Gadi L, Mony S, Meir M, Jaime G, Amir E, et al. Successful use of streptokinase for the treatment of empyema thoracis during advanced pregnancy: a case report. Respir Med CME. 2009;2(1):21–4.CrossRef
Metadaten
Titel
The use of fibrinolytic therapy for parapneumonic effusion in pregnancy: a case report and a review
verfasst von
Awrad Nasralla
Bryce Laing
Simon R. Turner
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
Journal of Cardiothoracic Surgery / Ausgabe 1/2021
Elektronische ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-021-01619-3

Weitere Artikel der Ausgabe 1/2021

Journal of Cardiothoracic Surgery 1/2021 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.